Aneurysmal bone cyst--clinical and morphological aspects.

AIM: To assess the results of surgical treatment in aneurysmal bone cysts. MATERIALS AND METHODS: 31 patients with aneurysmal bone cysts underwent surgical treatment in our department. In almost half of cases, the lesion was located in the femur. In 12 cases, a pathological bone fracture was the first clinical sign. The treatment consisted in curettage, abrasion of the cavity inner walls using a motorized burr and filling with morsellized bone grafts (autografts ± allografts) or bone substitutes (four cases). Microscopically, the diagnosis relies on cystic spaces filled with blood, divided by fibrous septae consisting in immature bone trabeculae, hemosiderin filled macrophages and fibroblasts. We performed multiple bioptic probes from different levels of the lesion. RESULTS: Macroscopically, the osseous lesion appeared as a multi-loculated blood-filled cavity (cavities separated by septa) in 30 (96.77%) cases and as a solid tumor in one (3.23%) case. At 12 months after surgery, grafts osteointegration was present in 24 cases. At an average follow-up time of six years and four months, refilling with bone grafts was necessary in two cases and no local recurrence was observed. CONCLUSIONS: Aneurysmal bone cyst is most frequent in the second decade of age. Its prevalence in female gender is double compared to the male gender. The positive diagnosis relies on the histopathological examination. Because of the strong relationship with a number of precursor lesions (giant cell tumor, fibrous dysplasia, non-ossifying fibroma, chondroblastoma, osteoblastoma) multiple bioptic probings are mandatory, in order to diagnose, if possible, a primary lesion, which may modify the therapeutic attitude. Treatment by curettage, abrasion of the cavity inner walls and filling with morsellized grafts has very good results. The risk of recurrence is very low.

Immunohistochemistry in diagnosis and surgical treatment of femoral bone metastasis.

BACKGROUND: When the primary tumor is unknown, the biopsy and the histopathological examination (associated with immunohistochemistry and molecular profiling) will identify the type and subtype of the tumor and, if possible, the site of origin. The classification in type and subtype will allow to assess the prognosis and to indicate the most appropriate therapeutic approach. AIM: Identification of the unknown primary tumor by biopsy and immunohistochemistry from the femoral bone metastasis, the clinical results and the survival rate after osteosynthesis ± cement stabilization of the lesion. PATIENTS AND METHODS: 52 patients with femoral metastasis were included in a prospective study. The gender ratio was 30 women/22 men (average age - 64 years and six months; range: 33-82 years). Thirty-three patients had pathologic bone fracture, while 19 had osteolytic lesions without fracture. The mean follow-up for survivors was 34 months (range: 17-56 months). Surgical treatment consisted in hemiarthroplasty, osteosynthesis with DHS (Dynamic Hip Screw), proximal femoral nail, locked centromedullary nail or DCS (Dynamic Condylar Screw) ± cement. In 19 (36.54%) cases, the primary tumor was not known. In these cases, biopsy and histological examination with immunochemistry were performed. Twenty-three (52.27%) patients underwent chemotherapy. Clinical and radiological check-ups were performed every three months in the first year and every six months after that. RESULTS: Pain was ameliorated in all cases. Deambulation was achieved in 45 out of 52 (86.54%) patients. Survival rate was 76.92% (40/52) at six months and 59.61% (31/52) at 12 months. At the end of the follow-up period, 18 (34.61%) patients were alive, 24 (46.15%) were deceased and 10 (19.23%) were lost to follow-up. After eliminating the patients lost to follow-up, the survival rate was 33.33% (9/27) in the pathologic fracture group and 60% (9/15) in the osteolytic lesion without fracture group. CONCLUSIONS: Most of the patients (86%) could be mobilized immediately after surgery. The expected survival rate one year after surgery is around 60%. The goals of osteosynthesis are the same, regardless the location of the lesion and the implant used: pain amelioration, appropriate stability for immediate full weight bearing, durability for patient's life expectancy. All extended osteolytic lesions must be reinforced at the time of the surgical procedure. The presence of a pathologic fracture is a negative prognosis factor for the medium term survival rate.